TEAM-HF
Clinical Trial

Your patients may be eligible to participate in this clinical trial

Team HF Clinical Trial

About the TEAM-HF Clinical Trial

The TEAM-HF clinical trial is a trial that will evaluate the benefit of earlier treatment of non-inotrope dependent advanced heart failure patients with the HeartMate 3™ LVAD compared to medical management alone. Refractory pulmonary hypertension (mPAP ≥ 30mmHg) as determined by remote pulmonary artery pressure monitoring using the CardioMEMS™ HF System will serve as an objective measure to identify patients at high risk of worsening heart failure.

Trial Design

This is prospective, randomized, open-label study of left ventricular assist device (LVAD) vs continued guideline directed medical therapy (GDMT) in non-inotrope dependent heart failure patients with refractory pulmonary hypertension secondary to left ventricular failure. The trial will randomize up to 500 patients at approximately 75 centers (~60 US-based centers and ~15 international centers). The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope-dependent advanced HF patients with elevated mean PAP refractory to GDMT. Subjects in this clinical investigation will be randomized between the HeartMate 3 LVAD and medical therapy in a 1:1 ratio.
 

HF Team Trial Design Chart

Eligibility Criteria*

Key Inclusion Criteria

  • New York Heart Association (NYHA) Functional Classification of  IIIB or IV
  • Left ventricular Ejection Fraction (LVEF ≤30%)
  • Cardiac Index < 2.2 L/min/m².
  • Limited functional status as demonstrated by 6-minute Walk Distance Test (6MWT) < 300 m due to heart failure related reasons.
  • Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months.
  • Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant.

Key Exclusion Criteria

  • Any use of inotrope therapy in the last 30 days.
  • Existence of ongoing Mechanical Circulatory support (MCS).
  • Contra-indications to HeartMate 3 LVAS or CardioMEMS HF system.
  • Etiology of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, severe valvular heart disease, or restrictive cardiomyopathy.
  • History of any solid organ transplant.
  • Presence of an active, uncontrolled infection.
  • Complex congenital heart disease.
  • Planned Ventricle Assisted Device (VAD) or Bi-VAD support prior to enrollment.

*Additional inclusion and exclusion criteria as listed on ClinicalTrials.gov

Clinical Trial Endpoints

Study Powered Primary Endpoint

Survival at 2 years, free of disabling stroke, reoperation to replace the device or worsening heart failure requiring listing for urgent heart transplantation, temporary mechanical circulatory support, enrollment into hospice or dependence on intravenous inotropes.

Study Powered Secondary Endpoint

Survival at 2 years.

To learn more about the TEAM-HF Trial, including eligibility criteria and study locations, please visit ClinicalTrials.gov website.

Learn More about Team HF
Learn More about Team HF

Sign Up for Updates from Abbott Heart Failure

Get Info

Caution: Investigational device. Limited by federal (or U.S.) law to investigational use as part of the TEAM-HF trial.

MAT-2415537 v1.0

CardioMEMS HF System Indications, Safety and Warnings

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS HF System Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

myCardioMEMS™ Mobile App Limitations: Patients must use their own Apple or Android mobile device to receive and transmit information to the myCardioMEMS Mobile App. To do so the device must be powered on, app must be installed and data coverage (cellular or Wi-Fi) available. The myCardioMEMS App can provide notification of medication adjustments and reminders, requests for lab work and acknowledgement that the PA pressure readings have been received. However there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of the notifications and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, clinic environment, schedule/configuration changes, or data processing.

MAT-2006766 v6.0

HeartMate 3 LVAD Indications, Safety and Warnings

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
 

HeartMate 3™ Left Ventricular Assist System

Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.

Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

HeartMate 3 Coring Tool

Indications: For the HeartMate 3 Left Ventricular Assist System (LVAS) Indications for Use, please refer to the HeartMate 3 LVAS Instructions for Use. The HeartMate 3™ Coring Tool is intended for use with the HeartMate 3 LVAS. The HeartMate 3 Coring Tool provides a means to resect a plug of myocardium from the left ventricle, which allows for HeartMate 3 inflow cannula insertion.

Contraindications: The use of the HeartMate 3 Coring Tool is contraindicated in patients who are contraindicated for HeartMate 3 Left Ventricular Assist System (LVAS) therapy.

Adverse Events: The following adverse events may be associated with the use of the HeartMate 3 Coring Tool. Adverse events are listed in anticipated decreasing order of frequency, except for death, which appears first as it is a non-reversible complication: death, bleeding (perioperative or late), local infection, local ischemia, cardiac arrhythmia, stroke, peripheral thromboembolic event, neurologic dysfunction, hemolysis, sepsis.

MAT-2012295 v3.0